A Single-Arm Study of Ebastine as Adjuvant Therapy in Patients With Tumor Budding-Positive Hepatocellular Carcinoma After Curative Hepatectomy
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 45
- 主要终点
- 1-Year Recurrence-Free Survival (RFS) Rate
研究概览
简要总结
This study evaluates ebastine, an FAK (focal adhesion kinase) inhibitor, as adjuvant therapy to reduce the risk of recurrence in patients with hepatocellular carcinoma (HCC) who have undergone curative hepatectomy and whose tumors show a histopathological feature known as tumor budding, which is associated with a higher risk of postoperative recurrence.
Ebastine is a second-generation antihistamine approved for allergic conditions. Preclinical studies have shown that ebastine also inhibits FAK signaling, a pathway implicated in tumor invasion, epithelial-mesenchymal transition, and recurrence. This study investigates whether administering ebastine after surgery can lower the recurrence risk associated with tumor budding-positive HCC.
All enrolled participants will receive ebastine as adjuvant treatment following hepatectomy. The primary endpoint is the 1-year recurrence-free survival (RFS) rate. Secondary endpoints include 2-year RFS, overall survival, and safety.
All participants in this study will receive ebastine as adjuvant (after-surgery) treatment. Researchers will monitor whether the cancer stays away for at least one year after surgery (recurrence-free survival), as well as overall survival and any side effects.
详细描述
Hepatocellular carcinoma (HCC) remains associated with a high rate of recurrence following curative hepatectomy, and tumor budding-a histopathological feature characterized by isolated single cells or small clusters of tumor cells at the invasive front-has been increasingly recognized as an independent adverse prognostic factor associated with epithelial-mesenchymal transition (EMT), local invasion, and early recurrence in multiple solid tumors, including HCC.
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that plays a central role in tumor cell adhesion, migration, invasion, and the EMT process that underlies tumor budding. FAK is frequently overexpressed and hyperactivated in HCC tissue and has been implicated in promoting a fibrotic, immunosuppressive tumor microenvironment that supports tumor progression and treatment resistance.
Ebastine, a second-generation H1-antihistamine widely used for allergic rhinitis and urticaria with a well-characterized long-term safety profile, has recently been identified through drug-repurposing research as a small-molecule inhibitor of FAK. Preclinical studies have demonstrated that ebastine binds the tyrosine kinase domain of FAK, blocking autophosphorylation at Y397 and Y576/577 residues, thereby attenuating downstream FAK-mediated signaling (including JAK2/STAT3 and MEK/ERK pathways) that drives tumor stem-cell-like properties, invasion, and metastasis in several solid tumor models, including triple-negative and HER2-positive breast cancer.
Given the mechanistic link between FAK signaling and tumor budding, and the favorable safety and tolerability profile of ebastine at its approved dose range, this study proposes to evaluate ebastine as an adjuvant therapy specifically in patients with tumor budding-positive HCC following curative hepatectomy-a population at elevated risk of early recurrence for whom effective, well-tolerated adjuvant options remain limited.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age is ≥18 years old, male or female;
- •Histologically confirmed as hepatocellular carcinoma without metastasis;
- •Tumor budding is positive
- •Life expectancy of at least 12 weeks;
排除标准
- •Hepatocellular carcinoma that cannot be surgically resected
- •Received radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc. before surgery
- •Pregnant or lactating women
- •Subjects with other malignant tumors;
- •Subjects who are considered unsuitable to participate in this cohort study by the investigator;
- •Subjects who refuse to enroll or do not sign the informed consent form;
- •Subjects with incomplete medical record information (including gender, age, diagnostic information, imaging (and) or pathological diagnosis results, other demographic data, etc.).
研究组 & 干预措施
Ebastine Adjuvant Treatment Arm
Participants with tumor budding-positive hepatocellular carcinoma who have undergone curative-intent hepatectomy will receive oral ebastine as adjuvant therapy.
干预措施: Ebastine (Drug)
结局指标
主要结局
1-Year Recurrence-Free Survival (RFS) Rate
时间窗: 1 year after surgery
Proportion of participants who remain free of tumor recurrence (local, regional, or distant) or death from any cause at 1 year after curative hepatectomy, as assessed by imaging (CT/MRI) per institutional standard follow-up protocol
次要结局
- 2-Year Recurrence-Free Survival (RFS) Rate(2 years after surgery)
- Overall Survival (OS)(Through study completion, approximately 3 years)
- Incidence of Treatment-Emergent Adverse Events(From first dose of ebastine through 30 days after last dose)